Actinogen Medical Limited (ASX:ACW)
Actinogen Medical is a biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Its management team, clinical and scientific advisory boards include world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.
Actinogen Medical’s drug candidate XanamemTM has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Additionally, the underlying mechanism of action through the inhibition of cortisol, offers Xanamem a broad platform of significant additional disease applications for which it can be developed, including diabetes cognitive impairment, PTSD and post-myocardial infarction.